Pharvaris N.V. (PHVS)
PHVS Stock Price Chart
Explore Pharvaris N.V. interactive price chart. Choose custom timeframes to analyze PHVS price movements and trends.
PHVS Company Profile
Discover essential business fundamentals and corporate details for Pharvaris N.V. (PHVS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Feb 2021
Employees
108.00
Website
https://pharvaris.comCEO
Berndt Axel Edvard Modig CPA,
Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
PHVS Financial Timeline
Browse a chronological timeline of Pharvaris N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.82.
Earnings released on 12 Aug 2025
EPS came in at -$0.94 falling short of the estimated -$0.87 by -8.05%.
Earnings released on 13 May 2025
EPS came in at -$0.89 falling short of the estimated -$0.80 by -11.25%.
Earnings released on 31 Mar 2025
EPS came in at -$0.93 .
Earnings released on 13 Nov 2024
EPS came in at -$0.85 falling short of the estimated -$0.66 by -28.79%.
Earnings released on 14 Aug 2024
EPS came in at -$0.59 falling short of the estimated -$0.57 by -3.51%.
Earnings released on 8 May 2024
EPS came in at -$0.56 matching the estimated -$0.56.
Earnings released on 3 Apr 2024
EPS came in at -$0.82 falling short of the estimated -$0.58 by -41.38%.
Earnings released on 2 Nov 2023
EPS came in at -$0.63 surpassing the estimated -$0.67 by +5.97%.
Earnings released on 7 Aug 2023
EPS came in at -$0.69 surpassing the estimated -$0.71 by +2.82%.
Earnings released on 8 May 2023
EPS came in at -$0.72 surpassing the estimated -$0.81 by +11.11%.
Earnings released on 5 Apr 2023
EPS came in at -$0.73 .
Earnings released on 8 Dec 2022
EPS came in at -$0.25 surpassing the estimated -$0.64 by +60.94%.
Earnings released on 1 Jul 2022
EPS came in at -$0.39 .
Earnings released on 11 May 2022
EPS came in at -$0.54 falling short of the estimated -$0.49 by -10.20%.
Earnings released on 29 Mar 2022
EPS came in at -$0.47 surpassing the estimated -$0.74 by +36.49%.
Earnings released on 10 Nov 2021
EPS came in at -$0.46 surpassing the estimated -$0.49 by +6.12%.
Earnings released on 30 Jul 2021
EPS came in at -$1.13 falling short of the estimated -$0.51 by -121.57%.
Earnings released on 26 May 2021
EPS came in at -$0.66 falling short of the estimated -$0.34 by -94.12%.
Earnings released on 30 Apr 2021
EPS came in at -$0.23 .
Earnings released on 30 Sept 2020
EPS came in at -$0.24 .
PHVS Stock Performance
Access detailed PHVS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.